


Accute Flaccid Paralysis (AFP) Surveillance Weekly Bulletin Early Warning Alert and Response Network - SYRIA

Epi Week 38 - Between 9/12/2021 and 9/18/2021

ADOC

Coverage



For previous AFP bulletins, please hit the link below:

<https://www.acu-sy.org/en/afp-reports/>

Accute Flaccid Paralysis (AFP) Surveillance Weekly Bulletin

Surveillance Highlights

2016

- (344) AFP cases have been reported.
- No new Polio (WPV) had been detected. (0) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (5.4), Stool Adequacy rate (81%), NPEV Isolation rate (23%) and Sabin-like Virus Isolation (4%).

2017

- (469) AFP cases have been reported.
- No new Polio (WPV) had been detected.
- (3) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (8.9), Stool Adequacy rate (89%), NPEV Isolation rate (23%) and Sabin-like Virus Isolation (4%).
- (70) cVDPV2 cases detected.

2018

- (399) AFP cases have been reported.
- No new Polio (WPV) have been detected.
- (1) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (10.8), Stool Adequacy rate (91%), NPEV Isolation rate (23%) and Sabin-like Virus Isolation (3%).
- (0) cVDPV2 cases detected.

2019

- (429) AFP cases have been reported.
- No new Polio (WPV) have been detected yet.
- (0) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (14.9), Stool Adequacy rate (91%), NPEV Isolation rate (23%) and Sabin-like Virus Isolation (8%).
- (0) cVDPV2 cases detected so far.

2020

- (386) AFP cases have been reported.
- No new Polio (WPV) have been detected yet.
- (0) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (10.2), Stool Adequacy rate (96%), NPEV Isolation rate (21%) and Sabin-like Virus Isolation (2%).
- (0) cVDPV2 cases detected so far.

2021

- (351) AFP cases have been reported.
- No new Polio (WPV) have been detected yet.
- (0) compatible cases classified by ERC.
- Key indicators: Non-polio AFP rate (12.8), Stool Adequacy rate (95%), NPEV Isolation rate (17%) and Sabin-like Virus Isolation (1%).
- (0) cVDPV2 cases detected so far.

Epi Week 38 - Between 9/12/2021 and 9/18/2021

Accute Flaccid Paralysis (AFP) Surveillance Weekly Bulletin


AFP Surveillance Key Indicators

	Pop<15			Expected 3/100,000			# of AFP cases			Non-Polio AFP Rate			Adequacy%			NPEV%			SL%			Median OPV			Median AGE		
	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021	2019	2020	2021
Aleppo	822,029	1,385,803	1,096,948	25	42	33	122	107	89	14.8	7.7	11.1	89	98	97	20	16	13	10	0	2	4	5	5	49	40	41
Idleb	1,051,574	1,448,147	1,230,444	32	43	37	162	107	80	15.4	7.4	8.9	87	93	91	22	20	9	5	1	0	6	6	5	30	38	39
Hama	72,103			2			1			4.0			100			0			0			9			96		
Ar-Raqqa	285,378	269,396	418,022	9	8	13	23	39	38	8.1	14.5	12.4	96	90	92	35	26	26	4	5	0	4	2	3	49	40	50
Deir-ez-Zor	194,183	242,085	532,407	6	7	16	65	75	60	33.5	31.0	15.4	95	99	100	37	25	28	12	5	2	4	5	4	28	31	34
Al-Hasakeh	446,353	429,405	481,635	13	13	14	56	58	84	12.5	13.5	23.9	96	98	94	14	21	16	9	0	1	5	5	4	52	73	53
Grand Total	2,871,620	3,774,836	3,759,456	86	113	113	429	386	351	14.9	10.2	12.8	91	96	95	23	21	17	8	2	1	5	5	5	37	41	43

Epi Week 38 - Between 9/12/2021 and 9/18/2021

Accute Flaccid Paralysis (AFP) Surveillance Weekly Bulletin









Epi Curve



Epi Week 38 - Between 9/12/2021 and 9/18/2021

Up to 9/18/2021


Total Indicators



Epi Week 38 - Between 9/12/2021 and 9/18/2021

Accute Flaccid Paralysis (AFP) Surveillance Weekly Bulletin



Indicators across Governorates



	Reporting				NP-AFP Rate.				Adequacy.				NPEV.				SL.			
	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021	2018	2019	2020	2021
Aleppo	107	122	107	89	12.2	14.8	7.7	11.1	87	89	98	97	20	20	16	13	3	10	0	2
Idleb	128	162	107	80	13.3	15.4	7.4	8.9	94	87	93	91	29	22	20	9	2	5	1	0
Hama	6	1			9.1	4.0			100	100			33	0			17	0		
Ar-Raqqa	38	23	39	38	14.9	8.1	14.5	12.4	87	96	90	92	31	35	26	26	0	4	5	0
Deir-ez-Zor	62	65	75	60	25.1	33.5	31.0	15.4	95	95	99	100	26	37	25	28	8	12	5	2
Al-Hasakeh	45	56	58	84	8.7	12.5	13.5	23.9	98	96	98	94	7	14	21	16	2	9	0	1
Homs	6				5.3				50				0				0			
R. Damascus																				
Dar'a	6				2.7				100				17				0			
Quneitra	1				4.3				100				0				0			
Grand Total	399	429	386	351	10.8	14.9	10.2	12.8	91	91	96	95	23	23	21	17	3	8	2	1


Epi Week 38 - Between 9/12/2021 and 9/18/2021

Indicators Maps




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2016




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2017




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2018




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2019




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2020




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Cases Distribution 2021




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Sex Distribution




Epi Week 38 - Between 9/12/2021 and 9/18/2021

Age Distribution





Epi Week 38 - Between 9/12/2021 and 9/18/2021

OPV Vaccination Status, 6-59 Months




Total OPV




Epi Week 38 - Between 9/12/2021 and 9/18/2021

OPV Vaccination Status 6 - 35 Months



Epi Week 38 - Between 9/12/2021 and 9/18/2021

OPV Vaccination Status 6 - 23 Months





Epi Week 38 - Between 9/12/2021 and 9/18/2021

Receiveness in Lab


Received In 3 Days
 Received in Lab within 3 days
 Have no samples collected
 Received in Lab within more than 3 days

Total Receiveness in Lab



Epi Week 38 - Between 9/12/2021 and 9/18/2021

Investigation within 48 Hours



Epi Week 38 - Between 9/12/2021 and 9/18/2021

Notification within 7 Days

